Delenex Therapeutics AG
Delenex Therapeutics AG closes CHF 7.3 (USD 8.0) million Series A3 Financing
Delenex Therapeutics AG / Key word(s): Capital Increase Delenex Therapeutics closes CHF 7.3 (USD 8.0) Million Series A3 Financing New capital will support a phase 2a clinical trial in topical treatment of psoriasis and advance additional PENTRA(R)Bodies to clinical-stage of development. Schlieren/Zurich, Switzerland – October 29, 2013 – Delenex Therapeutics AG, a biotechnology company developing topical and local treatments for dermatologic diseases using its proprietary PENTRA(R)Bodies, today announced the closing of a CHF 7.3 (USD 8.0) Million Series A3 round. All existing venture investors, HBM Ventures, Novo A/S, SV Life Sciences, BioMedinvest and Venture Incubator participated in the round. In addition, minority investors also participated. These proceeds will primarily be used to: 1. finish a phase 2a clinical study using the anti-TNF PENTRA(R)Body DLX105 in psoriasis, 2. advance the development of PENTRA(R)Bodies for the treatment of certain dermatologic 3. exploit the PENTRA(R) antibody and technology platform for the generation of novel products. This financing round brings Delenex’ total capital raised since inception to CHF 37.6 million. Executive Chairman Dr. Thomas Hecht said, ‘The findings of our ongoing psoriasis program and progress of earlier-stage projects provide a strong rationale for supporting additional investments in Delenex’ pipeline. We are confident that we can strengthen our dermatology franchise and also explore additional therapeutic areas with this continued financial support by our investors.’ CFO Jakob Schlapbach mentioned, ‘We are very pleased that all prior major investors engaged in this financing round on their pro rata basis. This shows the strong commitment of our investors to the promise of our products and platform.’ About Delenex Therapeutics AG Delenex is a privately-held biopharmaceutical company focused on the development of locally or topically applied antibody therapeutics. Thereby Delenex aims at extending the Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company). For further information, please contact: End of Corporate News +++++ Additional features: Document: http://n.equitystory.com/c/fncls.ssp?u=PNRTAICOCP Document title: 131029 Delenex Press Release 29.10.2013 This Corporate News was distributed by EQS Schweiz AG. www.eqs.com – news archive: http://switzerland.eqs.com/de/News The issuer is responsible for the contents of the release. |
236692 29.10.2013 |